Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Director · Chief Executive Officer | October 09, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date October 09, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,018,470 |
Reported balance
After 2026-10-09 transaction · row 1
1 source rowRow 1 · 2026-10-09 · Sale · Disposed 468,727 · Balance 4,018,470 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026 F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy: KVM Holdings, LLC | 1,030,771 |
Reported balance
After 2026-10-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-10-09 · Sale · Disposed 57,264 · Balance 1,030,771 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026 F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (3) to this Form 4. F4: The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026
F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4: The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 14, 2026 01:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 57,264 | $0.95 | $54,400.80 |
DisclosureSEC source: 0001628280-26-065797 · wk-form4_1791940019.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By: KVM Holdings, LLC Disclosed balance after: 1,030,771 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC. Read SEC document |
| October 09, 2026 Filed Oct 14, 2026 01:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 468,727 | $0.95 | $445,290.65 |
DisclosureSEC source: 0001628280-26-065797 · wk-form4_1791940019.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,018,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026 F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.90 to $0.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 09, 2026 Filed Sep 12, 2026 01:13 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 57,264 | $1.12 | $64,135.68 |
DisclosureSEC source: 0001628280-26-061626 · wk-form4_1789175624.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By: KVM Holdings, LLC Disclosed balance after: 1,088,035 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.11 to $1.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC. Read SEC document |
| September 09, 2026 Filed Sep 12, 2026 01:13 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 468,727 | $1.12 | $524,974.24 |
DisclosureSEC source: 0001628280-26-061626 · wk-form4_1789175624.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,487,197 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026 F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.06 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 3,123,201 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001470831-26-000020 · form4.xml · derivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,123,201 Underlying: Common Stock · 3,123,201 shares Expires 2036-01-02 F3 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 2, 2027, subject to continued service with the Issuer on the applicable vesting dates. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantCommon Stock | 3,123,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000020 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,955,924 F1 · kind: Reflects a grant of performance stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's common stock upon the achievement of certain performance goals, subject to continued service with the Issuer on the applicable vesting dates. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 22:01 UTC | Ocugen, Inc. OCGN · Entity 5550 | Tax withholdingCommon Stock | 177,146 | $0.89 | $158,457.10 |
DisclosureSEC source: 0001062993-25-000405 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,832,723 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:01 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 1,827,485 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001062993-25-000405 · form4.xml · derivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,827,485 Underlying: Common Stock · 1,827,485 shares Expires 2035-01-02 F2 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:47 UTC | Ocugen, Inc. OCGN · Entity 5550 | Tax withholdingCommon Stock | 180,204 | $0.65 | $117,673.21 |
DisclosureSEC source: 0001062993-24-000559 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,009,869 Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:05 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 492,126 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001062993-24-000474 · form4.xml · derivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,126 Underlying: Common Stock · 492,126 shares Expires 2034-01-02 F1 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 2, 2025, subject to continued service with the Issuer on the applicable vesting dates. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:11 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001062993-23-004080 · form4.xml · derivative · entry 5 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,764 Underlying: Common Stock · 100,000 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options, initially representing a right to purchase 1,357,145 shares, vest and become exercisable in equal annual installments over three years commencing on May 7, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:11 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 100,000 | $1.08 | $108,000.00 |
DisclosureSEC source: 0001062993-23-004080 · form4.xml · nonDerivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,190,073 F2 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.06 to $1.10. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:11 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 100,000 | $0.33 | $33,000.00 |
DisclosureSEC source: 0001062993-23-004080 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,290,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:12 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-23-001081 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,543 Underlying: Common Stock · 100,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 933,528 shares, vest and become exercisable in equal annual installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:12 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 100,000 | $1.28 | $128,000.00 |
DisclosureSEC source: 0001062993-23-001081 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,227,950 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.27 to $1.31. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:12 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 100,000 | $0.51 | $51,000.00 |
DisclosureSEC source: 0001062993-23-001081 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,327,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 1,771,654 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001062993-23-000487 · form4.xml · derivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,654 Underlying: Common Stock · 1,771,654 shares Expires 2033-01-03 F3 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 3, 2024, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantCommon Stock | 1,475,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000487 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,227,950 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Ocugen Inc.'s (the "Company's") common stock. The RSUs vest annually in three equal installments commencing on January 3, 2024, subject to continued service with the Company on the applicable vesting dates. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| January 03, 2023 Filed Feb 17, 2023 22:11 UTC | Ocugen, Inc. OCGN · Entity 5550 | Tax withholdingCommon Stock | 37,877 | $1.25 | $47,346.25 |
DisclosureSEC source: 0001062993-23-004080 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,190,073 F1 · date: This Form 4 is being filed late due to an administrative error. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 95,809 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-22-024210 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,543 Underlying: Common Stock · 95,809 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 933,528 shares, vest and become exercisable in equal annual installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 95,809 | $1.43 | $137,006.87 |
DisclosureSEC source: 0001062993-22-024210 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.39 to $1.54. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 95,809 | $0.51 | $48,862.59 |
DisclosureSEC source: 0001062993-22-024210 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 20:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-22-020804 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,352 Underlying: Common Stock · 100,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 933,528 shares, vest and become exercisable in equal annual installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 20:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 100,000 | $1.66 | $166,000.00 |
DisclosureSEC source: 0001062993-22-020804 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.63 to $1.74. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 20:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 100,000 | $0.51 | $51,000.00 |
DisclosureSEC source: 0001062993-22-020804 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001062993-22-016384 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,764 Underlying: Common Stock · 150,000 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 1,357,145 shares, vest and become exercisable in equal annual installments over three years commencing on May 7, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 150,000 | $2.72 | $408,000.00 |
DisclosureSEC source: 0001062993-22-016384 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.63 to $2.87. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 150,000 | $0.33 | $49,500.00 |
DisclosureSEC source: 0001062993-22-016384 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2022 Filed May 13, 2022 20:02 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001062993-22-012359 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,764 Underlying: Common Stock · 125,000 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 1,357,145 shares, vest and become exercisable in equal annual installments over three years commencing on May 7, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| May 13, 2022 Filed May 13, 2022 20:02 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 125,000 | $1.92 | $240,000.00 |
DisclosureSEC source: 0001062993-22-012359 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.90 to $1.96. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 13, 2022 Filed May 13, 2022 20:02 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 125,000 | $0.33 | $41,250.00 |
DisclosureSEC source: 0001062993-22-012359 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 81,823 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001062993-22-008132 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,764 Underlying: Common Stock · 81,823 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 1,357,145 shares, vest and become exercisable in equal annual installments over three years commencing on May 7, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 81,823 | $2.65 | $216,830.95 |
DisclosureSEC source: 0001062993-22-008132 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.61 to $2.75. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 81,823 | $0.33 | $27,001.59 |
DisclosureSEC source: 0001062993-22-008132 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001062993-22-004577 · form4.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,587 Underlying: Common Stock · 90,000 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options, initially representing a right to purchase 1,357,145 shares, vest and become exercisable in equal annual installments over three years commencing on May 7, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 90,000 | $3.74 | $336,600.00 |
DisclosureSEC source: 0001062993-22-004577 · form4.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.69 to $3.82. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 90,000 | $0.33 | $29,700.00 |
DisclosureSEC source: 0001062993-22-004577 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:32 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 1,253,299 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001062993-22-000699 · form4.xml · derivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253,299 Underlying: Common Stock · 1,253,299 shares Expires 2032-01-03 F3 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:32 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantCommon Stock | 346,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000699 · form4.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,540 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Ocugen Inc.'s (the "Company's") common stock. The restricted stock units vest annually in three equal installments commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates. The restricted stock units will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 02:23 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 197,000 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001104659-21-151343 · tm2135818-8_4seq1.xml · derivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,000 Underlying: Common Stock · 197,000 shares Expires 2031-04-19 F4 · derivative.exercise_price: Represents the closing price of the Company's common stock on the date of grant. See footnote 5 & 6 below. F5 · shares: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 985,000 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. F6 · shares: On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 197,000 shares. 98,500 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 98,500 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company. F5 · derivative.exercise_date: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 985,000 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. F6 · derivative.exercise_date: On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 197,000 shares. 98,500 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 98,500 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 02:23 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 115,000 | $5.22 | $600,300.00 |
DisclosureSEC source: 0001104659-21-151343 · tm2135818-8_4seq1.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: KVM Holdings, LLC Disclosed balance after: 1,145,299 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.03 to $5.39. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 197,000 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001192482-21-000755 · edgar.xml · derivative · entry 3 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,000 Underlying: Common Stock · 197,000 shares Expires 2031-04-19 F4 · derivative.exercise_price: Represents the closing price of the Company's common stock on the date of grant. See footnote 5 below. F5 · shares: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 985,000 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 197,000 shares. 98,500 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 98,500 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company. F5 · derivative.exercise_date: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 985,000 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 197,000 shares. 98,500 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 98,500 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 115,000 | $8.04 | $924,600.00 |
DisclosureSEC source: 0001192482-21-000755 · edgar.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By: KVM Holdings, LLC Disclosed balance after: 1,260,299 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.86 to $8.22. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:38 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 115,367 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001891015-21-000010 · edgar.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,352 Underlying: Common Stock · 115,367 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, initially representing a right to purchase a total of 933,528 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:38 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 115,367 | $14.15 | $1,632,443.05 |
DisclosureSEC source: 0001891015-21-000010 · edgar.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,000 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.07 to $14.33. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:38 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 115,367 | $0.51 | $58,837.17 |
DisclosureSEC source: 0001891015-21-000010 · edgar.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 20:02 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001192482-21-000741 · edgar.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,076,587 Underlying: Common Stock · 125,000 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, initially representing a right to purchase a total of 1,357,145 shares, vests and becomes exercisable annually in equal installments over three years commencing on May 7, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 20:02 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 125,000 | $9.80 | $1,225,000.00 |
DisclosureSEC source: 0001192482-21-000741 · edgar.xml · nonDerivative · entry 2 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,000 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.67 to $10.06. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 20:02 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 125,000 | $0.33 | $41,250.00 |
DisclosureSEC source: 0001192482-21-000741 · edgar.xml · nonDerivative · entry 1 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:01 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001192482-21-000724 · edgar.xml · derivative · entry 4 Musunuri Shankar · CIK 0001791820 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201,587 Underlying: Common Stock · 125,000 shares Expires 2030-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, initially representing a right to purchase a total of 1,357,145 shares, vests and becomes exercisable annually in equal installments over three years commencing on May 7, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.